Targets › CD84
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.
Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. (UniProt, Q9UIB8)
Open in Phaseline: the race on CD84, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gyala Therapeutics | GYA01 (CART84) anti-CD84 chimeric antigen receptor (CAR) T-cell therapy | CD84 | Phase 1 | Acute Myeloblastic Leukaemia | May 2029 |
Acute Myeloblastic Leukaemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.